A review of the pathogenic mechanism and clinical management progress of in-stent calcification restenosis - Report - MDSpire

A review of the pathogenic mechanism and clinical management progress of in-stent calcification restenosis

  • By

  • Xiangchen Xia

  • Fei Luo

  • Jianchun Li

  • Quanyi Liu

  • Jianzhong Pang

  • Fuyun Jia

  • Qiang Xu

  • Chao Peng

  • May 29, 2026

Share

Clinical Report: Advances in Management of In-Stent Restenosis Due to Calcification

Overview

Calcific in-stent restenosis (ISR) poses significant challenges in coronary interventions, impacting long-term patient outcomes. Recent advancements in imaging and therapeutic techniques have improved the understanding and management of this condition.

Background

In-stent calcific restenosis is a major complication following percutaneous coronary intervention (PCI), characterized by complex mechanisms that hinder effective treatment. The presence of calcification can lead to inadequate stent expansion and increased risk of restenosis, making it crucial to develop effective management strategies. Understanding the pathophysiology and utilizing advanced imaging techniques are essential for optimizing treatment outcomes in patients with calcified lesions.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • Calcification restricts stent expansion and exacerbates neointimal hyperplasia and neoatherosclerosis.
  • High-resolution intravascular imaging (OCT/IVUS) allows for precise evaluation of calcification characteristics.
  • Intravascular lithotripsy (IVL) selectively disrupts calcific plaque with minimal adjacent soft-tissue injury.
  • Conventional treatment modalities often face limitations in severe calcification cases.
  • High-density calcification correlates with lower restenosis rates compared to lower-density calcification.

Clinical Implications

Clinicians should consider advanced imaging techniques to assess calcification characteristics before selecting treatment strategies for ISR. The integration of novel therapies such as IVL and hybrid approaches may enhance procedural success in managing calcified lesions.

Conclusion

The management of calcific ISR is evolving with advancements in imaging and therapeutic technologies, providing new avenues for improving patient outcomes in coronary interventions.

Related Resources & Content

  1. Clinical Research in Cardiology, 2026 -- In-hospital outcomes of intravascular lithotripsy compared to rotational atherectomy and cutting/scoring balloon angioplasty
  2. Clinical Research in Cardiology, 2025 -- Ideal Stent Expansion Metrics for Assessing Outcomes in Percutaneous Coronary Intervention of Calcified Coronary Lesions
  3. Frontiers in Medicine, 2026 -- Recent advances in percutaneous coronary intervention for modernizing coronary physiology-guided and device-based strategies for coronary revascularization
  4. SCAI Expert Consensus Statement on the Management of Calcified Coronary Lesions, 2024
  5. PubMed, 2024 -- Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial
  6. Basic Research in Cardiology — The Role of Innate Immune Cells in Calcific Aortic Valve Disease Pathophysiology: Insights from Atherosclerotic Cardiovascular Disease
  7. SCAI Expert Consensus Statement on the Management of Calcified Coronary Lesions - ScienceDirect
  8. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial - PubMed
  9. Immediate and Midterm Efficacy and Safety of Intravascular Lithotripsy for Calcified In-Stent Restenosis: A Systematic Review and Meta-Analysis - PubMed

Original Source(s)

Related Content